Jakavi (INC424, ruxolitinib) is a JAK 1 and JAK 2 inhibitor approved for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar tissue. Since the abnormal marrow can no longer produce enough normal blood cells, the spleen often becomes enlarged when it takes responsibility for blood cell creation. Patients may also suffer debilitating symptoms including fever, extreme fatigue, intractable pruritus (itchiness), night sweats, weight loss, bone or muscle pain, poor quality of life and shortened survival.1 JAKAVI directly targets the underlying mechanism of disease, significantly reducing the size of the spleen in patients with myelofibrosis and relieving symptoms regardless of JAK mutational status, disease subtype, or any prior treatment, including hydroxyurea.
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
Novartis licensed INC424 (ruxolitinib) from Incyte for development and commercialization outside the US. Incyte has retained rights for the development and commercialization of INC424 (ruxolitinib) in the US.
1Mesa RA, Schwagera S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33:1199-1203.